

Efficacy of Quetiapine in Parkinson's Psychosis

Submission date 14/07/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 09/09/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 06/10/2009	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Anthony David

Contact details

Institute of Psychiatry
P.O. Box 68
De Crespigny Park
Denmark Hill
London
United Kingdom
SE5 8AF
+44 (0)207 848 0138
A.David@iop.kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

KCL/KCH-CT2004-1

Study information

Scientific Title

Acronym

EQuiPP

Study objectives

The study hypothesis is that Quetiapine is effective in the treatment of the psychotic symptoms (hallucinations/delusions) seen in Parkinson's disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised placebo controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Parkinson's disease

Interventions

Quetiapine versus Placebo

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Quetiapine

Primary outcome measure

1. Improvement in psychotic symptoms
2. Parkinsonian symptoms
3. Depressive symptoms
4. Remaining in the trial for the 12 week duration (patients will be withdrawn if their psychotic symptoms worsen)

Secondary outcome measures

1. Activities of daily living
2. Cognitive function
3. Carer burden

Overall study start date

01/08/2005

Completion date

01/08/2006

Eligibility**Key inclusion criteria**

1. Hallucinations, delusions of a severity >3/7 on the Brief Psychiatric Rating Scale, 2. Diagnosis of Parkinson's which meets UKPD Society Brain Bank criteria

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

60

Key exclusion criteria

1. Anti-psychotic medication in the preceding 3 months
2. Any contra-indication to quetiapine
3. Any important drug interactions
4. Major concomitant medical illness
5. History of uncontrolled diabetes or hypertension
6. Changes in medication in the last 14 days

Date of first enrolment

01/08/2005

Date of final enrolment

01/08/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Institute of Psychiatry

London

United Kingdom

SE5 8AF

Sponsor information

Organisation

King's College London (UK)

Sponsor details

c/o Gill Dale

P.O. Box 005

The Institute of Psychiatry

De Crespigny Park

Denmark Hill

London

England

United Kingdom

SE5 8AF

Sponsor type

University/education

Website

<http://www.iop.kcl.ac.uk>

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Charity

Funder Name

Parkinson's Disease Society (UK) (Ref: 4052)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2009		Yes	No